Advances in Developing CAR T-Cell Therapy for HIV Cure

Area of Science:

• Immunology
• Virology
• Biotechnology

Background:

• Acquired immune deficiency syndrome (AIDS), caused by Human Immunodeficiency Virus (HIV), remains a global epidemic despite advances in combination antiretroviral therapy (cART).
• cART effectively suppresses HIV replication but cannot eradicate latently infected cells, necessitating lifelong treatment with associated toxicities, costs, and stigma.
• The persistence of viral reservoirs necessitates the development of novel therapeutic strategies aimed at achieving a functional HIV cure.

Purpose of the Study:

• To review and compare potential therapeutic strategies for achieving an HIV cure.
• To focus on the potential of chimeric antigen receptor-modified T cells (CAR T) as a novel approach to eliminate the HIV viral reservoir.

Main Methods:

• Literature review and comparative analysis of existing and emerging HIV cure strategies.
• Exploration of the mechanisms and potential applications of CAR T-cell therapy in the context of HIV infection.

Main Results:

• Combination antiretroviral therapy (cART) is effective in viral suppression but not eradication.
• Latent HIV reservoirs pose a significant barrier to a complete cure.
• CAR T-cell therapy presents a promising avenue for targeting and eliminating these reservoirs.

Conclusions:

• Novel therapeutic strategies are essential to overcome the limitations of current HIV treatments.
• Chimeric antigen receptor (CAR) T-cell therapy holds significant potential as a curative approach for HIV by targeting latent viral reservoirs.
• Further research and clinical investigation are warranted to optimize CAR T-cell therapy for HIV eradication.